These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6999103)

  • 1. Thrombosis and sex hormones: a perplexing liaison.
    Wessler S
    J Lab Clin Med; 1980 Nov; 96(5):757-61. PubMed ID: 6999103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives.
    Gordon EM; Ratnoff OD; Saito H; Donaldson VH; Pensky J; Jones PK
    J Lab Clin Med; 1980 Nov; 96(5):762-9. PubMed ID: 7419960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].
    Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H
    Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
    van Vliet HA; Frolich M; Christella M; Thomassen LG; Doggen CJ; Rosendaal FR; Rosing J; Helmerhorst FM
    Hum Reprod; 2005 Feb; 20(2):563-8. PubMed ID: 15539435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive risks: a realistic appraisal.
    Bressler R; Durand JL
    Drug Ther (NY); 1979 Oct; 9(10):81-95. PubMed ID: 12279276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
    Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives and thromboembolism.
    IPPF Med Bull; 1967; 1(5):4. PubMed ID: 12304982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.
    Hannaford PC; Kay CR
    Br J Gen Pract; 1998 Oct; 48(435):1657-62. PubMed ID: 10071398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vascular disease and hormonal treatment--epidemiology].
    Vessey MP
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):121-6. PubMed ID: 12280197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors.
    Tanis BC; Rosendaal FR
    Semin Vasc Med; 2003 Feb; 3(1):69-84. PubMed ID: 15199494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal state rather than age influences cut-off values of protein S: reevaluation of the thrombotic risk associated with protein S deficiency.
    Liberti G; Bertina RM; Rosendaal FR
    Thromb Haemost; 1999 Sep; 82(3):1093-6. PubMed ID: 10494769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thrombosis, oral contraceptives and high factor VIII levels.
    Bloemenkamp KW; Helmerhorst FM; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1999 Sep; 82(3):1024-7. PubMed ID: 10494758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of oral contraceptive-induced thrombosis.
    Pizzo SV
    Drug Ther (NY); 1981 Sep; 11(9):101-8. PubMed ID: 12263495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.
    Pomp ER; le Cessie S; Rosendaal FR; Doggen CJ
    Br J Haematol; 2007 Oct; 139(2):289-96. PubMed ID: 17897305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives.
    Hölschermann H; Terhalle HM; Zakel U; Maus U; Parviz B; Tillmanns H; Haberbosch W
    Thromb Haemost; 1999 Dec; 82(6):1614-20. PubMed ID: 10613644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.